Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
A team of researchers at the University of the Pacific has developed an injectable version of Narcan that releases the opioid ...
A University of Pacific professor and his team developed a drug delivery system that they say could offer a game-changing ...
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...